dr. reckamp on cabozantinib plus erlotinib for advanced egfr-mutant nsclc
Published 10 years ago • 323 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:02
dr. reckamp on mk-2206 for the treatment of egfr wild-type nsclc
-
1:07
dr. rekamp discusses a phase ii study mk-2206 plus erlotinib in nsclc
-
1:11
dr. reckamp on targeted therapy options for rare mutations in nsclc
-
1:15
dr. rizvi on nivolumab plus erlotinib in patients with egfr mt nsclc
-
1:02
dr reckamp on amivantamab in egfr exon 20–mutated nsclc
-
5:51
karen reckamp, md, ms: results in phase ii advanced lung cancer trial
-
1:56
dr. haigentz on the potential of erlotinib and bevacizumab in egfr-mutant nsclc
-
4:20
erlotinib plus ramucirumab for egfr mutant lung cancer
-
6:41
relay: erlotinib with ramucirumab for egfr nsclc
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
1:13
dr. reckamp on pivotal data in metex14-altered nsclc
-
0:58
dr. papadimitrakopoulou on treatment options for egfr-mutant nsclc
-
0:32
dr. reckamp discusses the use of hsp90 inhibitors
-
0:56
belief: phase 2 trial of erlotinib plus bevacizumab for non-small cell lung cancer
-
0:49
dr. reckamp on molecular testing in lung cancer
-
1:10
ronald natale on treatment options for egfr-mutant lung cancer
-
1:02
are egfr tkis (such as tarceva) effective in lung cancer patients who are wild type egfr?
-
1:04
dr. kris discusses egfr mutation testing
-
2:35
cabozantinib most effective treatment for metastatic papillary kidney cancer